UK-India pharma corridor: The UK pharmaceutical sector spent £9.3 billion on research and development in 2024. Pharmaceutical manufacturing produced £20.4 billion in gross value added in 2023. Yet exports fell to £24.7 billion in 2024, while imports rose to £25.9 billion. Britain retains formidable research capacity, but its position in manufacturing and trade is weaker than its reputation suggests.
India starts from the other end of the industry. It supplies about a fifth of the world’s generic medicines and has a large base in formulations, vaccines and active pharmaceutical ingredients. Its pharmaceutical companies are trying to move into biosimilars and other research-intensive products.
READ | Pharma market growth shifts to chronic care
A UK-India pharmaceutical corridor therefore has a commercial logic. Britain offers laboratories, clinical institutions, health data and regulatory experience. India offers process chemistry and manufacturing at scale. The opportunity lies in linking these assets through products, trials, licensing agreements and supply contracts.
UK pharmaceutical industry
The UK data show a sector built around research rather than volume production. Pharmaceutical R&D accounted for 17 per cent of business R&D spending in 2024. Britain was behind only Switzerland and Belgium when pharmaceutical R&D was measured as a share of gross domestic product using the latest comparable data.
The National Health Service shapes the domestic medicines market. Companies must secure an authorisation from the Medicines and Healthcare products Regulatory Agency and, for NHS use in England, usually pass an assessment by the National Institute for Health and Care Excellence.
Two changes have improved the terms for innovative medicines. NICE raised its standard cost-effectiveness range from £20,000-£30,000 to £25,000-£35,000 for each quality-adjusted life year. The change took effect in April 2026. The payment rate on eligible sales of newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth fell from 22.9 per cent in 2025 to 14.5 per cent in 2026.
A drug company can therefore clear NICE at a higher cost-per-QALY level and surrender a smaller share of eligible sales than it did last year. The NHS remains a demanding buyer, but the economics of launching some patented medicines have improved.
READ | Pharmaceutical industry risks rise amid US tariff threat
UK pharma regulation rests on MHRA, NICE and the NHS
The MHRA decides whether a medicine meets the required standards of safety, quality and efficacy. NICE examines whether its benefits justify the price sought from the NHS. The NHS then becomes the principal purchaser and delivery system.
The Association of the British Pharmaceutical Industry represents research-based drug companies and negotiates with the government on pricing arrangements such as VPAG. The Royal Pharmaceutical Society sets professional standards for pharmacists. The National Pharmacy Association represents independent community pharmacies.
For an overseas manufacturer, the MHRA, NICE and NHS decisions carry the greatest commercial weight. Regulatory approval does not ensure reimbursement, while a favourable NICE decision has limited value without adequate production and supply.
The UK has also aligned parts of the MHRA and NICE review processes. The pathway launched in 2026 allows licensing and value assessments to run in parallel. The two bodies estimate that some medicines could reach NHS patients three to six months earlier. The Innovative Licensing and Access Pathway provides earlier advice on evidence generation and development plans.
UK clinical trials are recovering from a weak base
Oxford, Cambridge and London remain the core of British drug discovery. University laboratories, teaching hospitals, venture funds and pharmaceutical companies are concentrated within a relatively small area. The country also offers a 10 per cent corporation tax rate on qualifying profits from patented inventions through the Patent Box.
Industry data show that 578 commercial trials were initiated in 2024, up from 426 in 2023. Government figures published in April 2026 put the average set-up time for commercial trials at 122 days in the first half of 2025-26, compared with 169 days a year earlier.
The recovery follows a poor period. An international comparison using an older and broader measure put the median UK time from regulatory application to the first patient’s first dose at 338 days in 2023. Britain ranked last among ten comparator countries. The two measures cover different stages, but the contrast shows the size of the repair job.
Indian companies can use UK hospitals for trials involving complex medicines, rare diseases and products requiring specialist clinical oversight. British trial data can support submissions prepared to International Council for Harmonisation standards. The MHRA also participates in the Access Consortium with regulators from Australia, Canada, Singapore and Switzerland.
MHRA approval does not replace a separate decision by the US Food and Drug Administration or other national regulators. It can, however, give an Indian sponsor a dossier developed under widely recognised standards and access to regulatory work-sharing among Access Consortium members.
UK pharmaceutical trade has slipped into deficit
Britain exported £24.7 billion of pharmaceutical products in 2024, down from £25.6 billion in 2023. Imports rose to £25.9 billion. The UK was therefore a net importer of pharmaceutical goods in 2024.
This creates room for Indian manufacturers, though price alone will not secure NHS business. Suppliers must meet MHRA requirements, pass procurement checks and demonstrate that they can maintain supply when raw material, freight or production disruptions occur.
The UK-India Comprehensive Economic and Trade Agreement entered into force on July 15, 2026. The agreement reduces tariffs on a range of products, improves customs procedures and establishes rules covering technical barriers to trade. The UK government expects pharmaceuticals to be among the chemical-sector products that gain from lower Indian tariffs.
The agreement does not confer automatic access to NHS contracts or waive medicines regulation. Its pharmaceutical value lies mainly in reducing friction around investment, customs, technical discussions and the movement of specialised staff.
UK-India pharma corridor offers four commercial routes
Complex biologics and biosimilars
Indian companies have built their international businesses around generic medicines. The next step requires more demanding products, including biosimilars and biologics.
British universities and early-stage companies often possess promising molecules or platforms but lack the capital or production capacity required for late-stage development. Indian manufacturers can provide process development, clinical batches and commercial production. Joint ventures and licensing agreements would allow Indian firms to enter higher-value segments without having to build every discovery capability at home.
Clinical development and regulatory preparation
Indian sponsors can run parts of their global clinical programmes through UK hospitals and research networks. Early discussions with the MHRA and NICE can help a company design trials that address both licensing and reimbursement requirements.
READ | India-China pharma trade opens up a $6 bn opportunity
This is more useful than treating MHRA approval as a badge acquired at the end of development. Evidence standards, comparators and trial endpoints decided early can determine whether a product secures NHS use after it receives a marketing authorisation.
NHS supply and manufacturing contracts
Indian firms already compete effectively in high-volume generic markets. The NHS offers scale, but its tendering system rewards low prices and reliable delivery.
The stronger opening lies in long-term contracts covering finished medicines, active ingredients and contract manufacturing. Indian firms will need UK inventory, distribution and pharmacovigilance arrangements rather than relying solely on shipments from domestic factories.
The trade agreement can support these supply chains. It cannot compensate for a failed inspection, an interrupted production line or a missed NHS delivery schedule.
Health data and patient recruitment
Our Future Health had more than two million consented participants by July 2026. Data for 755,000 genotyped participants were available, together with questionnaire information and linked health records. The programme stores the data in a trusted research environment. Researchers require an approved study and must meet its data-governance conditions.
Indian contract research organisations and drug companies could use such resources through approved collaborations with British institutions. The immediate applications include identifying suitable patient groups, testing study designs and improving trial recruitment. The data are not an unrestricted commercial asset and cannot be copied into private drug-discovery systems.
The UK-India pharmaceutical corridor will acquire substance when British discoveries enter Indian production lines, Indian sponsors enrol patients in UK trials, and medicines developed through these partnerships reach the NHS and other regulated markets. Without such transactions, the corridor remains a diplomatic label.
Kumar Kuntikanamata is Councillor in Fleet Town council, Hampshire, UK. He is an expert in pharma industry and worked for many global firms. He has also worked as Vice Chairman for British South India Council of Commerce.